Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma
INDIAN JOURNAL OF PHARMACOLOGY, vol.46, no.1, pp.125-126, 2014 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 46 Issue: 1
- Publication Date: 2014
- Doi Number: 10.4103/0253-7613.125195
- Journal Name: INDIAN JOURNAL OF PHARMACOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.125-126
- Hacettepe University Affiliated: Yes
Abstract
Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.